546-A The Preclinical Pharmacokinetics and Safety Pharmacology of the Anti-HIV CCR5 Antagonist, UK-427, 857 C. Napier*1, P. Dorr1, R. Gladue2, R. Halliday1, D. Leishman1, I. Machin1, R. Mitchell1, A. Nedderman1, M. Perros1, S. Roffey1, D. Walker1, R. Webster1 1Pfizer Global R&D, Sandwich Labs, Kent, UK and 2Pfizer Global R&D, Groton Labs, CT